Key result
GLP-1 receptor agonists modify cardio-reno-metabolic disease outcomes beyond glycemic control in patients with type 2 diabetes mellitus.
Why the study?
Do GLP-1 receptor agonists improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus?
Do GLP-1 receptor agonists improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus?
An editorial discussing the evolving role of GLP-1 receptor agonists in cardio-reno-metabolic disease modification for patients with type 2 diabetes.
This invited editorial refers to ‘Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-an
No takes yet. Share an insight, caveat, or question.
Farmakis et al. (2026) studied this question. GLP-1 receptor agonists modify cardio-reno-metabolic disease outcomes beyond glycemic control in patients with type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: